Development of anti-HER2 monoclonal antibodies for gastric cancer

被引：0
|
作者：
Nanamiya, Ren [1 ]
Suzuki, Hiroyuki [2 ]
Kato, Yukinari [1 ,2 ]
机构：
[1] Tohoku Univ, Dept Antibody Drug Dev, Grad Sch Med, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Mol Pharmacol, Grad Sch Med, Sendai, Miyagi, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1164
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [41] Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
    Shak, S
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 71 - 77
  • [42] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [43] In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
    Larbouret, Christel
    Robert, Bruno
    Navarro-Teulon, Isabelle
    Thezenas, Simon
    Ladjemi, Maha-Zohra
    Morisseau, Sebastien
    Campigna, Emmanuelle
    Bibeau, Frederic
    Mach, Jean-Pierre
    Pelegrin, Andre
    Azria, David
    CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3356 - 3362
  • [44] Preparation and biological activities of anti-HER2 monoclonal antibodies with multibranched complex-type N-glycans
    Takashima, Shou
    Kurogochi, Masaki
    Tsukimura, Wataru
    Mori, Masako
    Osumi, Kenji
    Sugawara, Shu-ichi
    Amano, Junko
    Mizuno, Mamoru
    Takada, Yoshio
    Matsuda, Akio
    GLYCOBIOLOGY, 2021, 31 (10) : 1401 - 1414
  • [45] Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
    Muntasell, Aura
    Cabo, Mariona
    Servitja, Sonia
    Tusquets, Ignasi
    Martinez-Garcia, Maria
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Lopez-Botet, Miguel
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [46] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
  • [48] Anti-HER2 therapy for breast cancer in older patients
    Goldner, Marcelle
    Franzoi, Maria A.
    Lago, Lissandra D.
    Ponde, Noam
    FUTURE ONCOLOGY, 2020, 16 (19) : 1393 - 1407
  • [49] Anti-HER2 imaging agents for breast cancer imaging
    Tolner, B.
    Vigor, K.
    Mather, S.
    Robinson, M.
    Adams, G.
    Plueckthun, A.
    Chester, K.
    BREAST CANCER RESEARCH, 2010, 12 : S13 - S13
  • [50] Developing anti-HER2 vaccines: Breast cancer experience
    Al-Awadhi, Aydah
    Lee Murray, James
    Ibrahim, Nuhad K.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (09) : 2126 - 2132
12345